5Suarez AG, Floyd K, Portcoarrero J, et al. Feasibility and cost-effectiveness of standardized second-line drug treatment for chronic tuberculosispatients: a national cohort study in Peru [J]. The Lancet,2002; 359: 181- 190.
6Borgdorff MW, Flord K, Broekmans JF. Interventions to reduce tuberculosis mortality and transmission in low-and middel-income countries[R]. Bulletin of the World Health Organization, 2002; 80 (3): 217-287.
7Tiruviluarnala P, Reichmen LB. Tuberculosis [J]. Annual review of public health, 2002, 23 ( 1 ): 403 - 424.
8Farmer P, Kim JY. Community based approaches to the control of multidrugresistant tuberculosis: introducing "DOTS-plus" [J]. BMJ,1998; 317: 617-670.
9Sterling TR, Lehmann HP, Frieden TR. Impact od DOTS compared with DOTS-plus on multidrug resistant tuberculosis and tuberculosis deaths: decision analysis [J]. BMJ, 2003; 326: 577-582.
10Ariel PM, GowdaDK, FriedenTR, etal. Controllingmultidrug-resistant tuberculosis and access to expensive drug: arational framework[R]. Bulletin of the World Health Organization, 2002, 80 (6) LA95-496.
